Skip to main content
Fig. 3 | Health and Quality of Life Outcomes

Fig. 3

From: Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant

Fig. 3

Change in the SDS score among patients included in the study using MMRM. AD + PBO, oral antidepressant plus placebo nasal spray; CI, confidence interval; ESK + AD, esketamine nasal spray plus oral antidepressant; LSM, least square mean; MMRM, mixed-effects model using repeated measures; SDS, Sheehan Disability Scale; SE, standard error. aTest for treatment effect is based on mixed model for repeated measures (MMRM) with change from baseline as the response variable and the fixed effect model terms for treatment), day, country, class of oral antidepressant (SNRI or SSRI), and treatment-by-day and baseline value as a covariate. A negative difference favors the ESK + AD group. Note: SDS total score ranges from 0 to 30; a higher score indicates greater impairment. Negative change in score indicates improvement

Back to article page